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COPD treatment choices based on blood eosinophils
Key points
●● Eosinophilia may play a significant role in the pathogenesis of COPD.
●● Eosinophilic inflammation in COPD can be steroid responsive; however, eosinophilic inflammation 
is variable, and caution needs to be taken with measurements and the thresholds used.
●● The long-term effects of reducing eosinophil levels in COPD is unclear.
Educational aims
●● To explore current knowledge of eosinophils in COPD.
●● To explore the relationship between eosinophilia and corticosteroid use.
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Eosinophilia is common in COPD and has utility in predicting responses to inhaled or oral 
corticosteroids, but has limitations as a biomarker http://bit.ly/2lQcMpy
Eosinophils are increasingly being recognised as an important characteristic feature of COPD. 
Patients with COPD and eosinophilic inflammation tend to respond to steroid therapy; however, 
many questions remain regarding the optimum measurement. Eosinophilic inflammation may 
be defined based on various sampling techniques, including eosinophil levels in blood, sputum, 
bronchoalveolar lavage or biopsy, which leads to inconsistencies in its definition. Blood eosinophils 
may increase in conjunction with sputum eosinophils during COPD exacerbations and therefore 
may be a good surrogate marker of airway eosinophilic inflammation. However, the timing of the 
blood eosinophil measurement, the stability of the eosinophil count and the threshold used in 
different studies are variable. The use of blood eosinophil count to direct biological therapies in 
COPD has also had variable outcomes. Eosinophilic inflammation has an important role in COPD 
management; however, its use as the optimum biomarker still needs further investigation.
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Review
COPD treatment choices 
based on blood eosinophils: 
are we there yet?
What is an eosinophil, and 
are these cells needed?
Eosinophils are one of several types of leukocyte 
found in peripheral blood and in tissues, and in 
some lung diseases they are found in both lung 
tissue and in the airway and/or alveolar lumen. They 
are classified and referred to as both granulocytes 
(due to the numerous granules in their cytoplasm) 
and polymorphonuclear leukocytes (due to their 
irregularly shaped nucleus). It is worth noting that 
the term polymorphonuclear leukocyte sometimes 
causes confusion as it is used incorrectly to refer 
only to neutrophils.
Eosinophils are evolutionarily old, being found in 
“living fossils” such as the tuatara, a type of lizard 
found in New Zealand [1]. They are also present 
and functionally similar across multiple species; 
for example, they are found in zebrafish where 
they increase in number in response to parasitic 
worm infections [2]. However, the exact function 
of the eosinophil remains something of a mystery. 
Classically, and as alluded to, eosinophils are 
described as important immune cells that control 
parasitic worm infections; however, the evidence 
for this is based on historical pathological studies 
and may not be correct. For example, studies in 
mice have shown that the absence of eosinophils 
promotes the death of the natural mouse worm 
Trichinella spiralis [3], adding further to the mystery 
of their exact biological role. There is also now 
the idea that eosinophils are the immunological 
equivalent of the appendix. This has largely 
stemmed from the use of anti-interleukin (IL)-5 
biologicals for the treatment of allergic disorders 
including asthma, in which the absence of 
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eosinophils does not lead to adverse immunological 
consequences. Of interest in the context of COPD, 
in which the neutrophil is thought to drive tissue 
damage, eosinophils have a greater capacity to 
produce reactive oxygen species [4], and therefore 




Studies in the 1940s and 1950s recognised that 
raising the levels of endogenous corticosteroids 
or administration of synthetic corticosteroids 
decreased eosinophil counts [5, 6] and, over 
20 years ago, studies emerged demonstrating 
a direct pro-apoptotic effect of corticosteroids 
on eosinophil apoptosis [7]. Therefore, it is not 
surprising today to find that eosinophilia in a 
range of diseases is supressed by either inhaled 
corticosteroid (ICS) or systemic corticosteroid 
treatment. It would therefore be easy to assume 
that eosinophilic COPD should be corticosteroid 
responsive; however, in COPD, the effect of 
corticosteroid treatment on eosinophil levels and/
or clinical outcomes is not as straightforward. Today 
we acknowledge that COPD is a heterogeneous 
disease, both in its aetiology and clinical course [8]. 
What perhaps is more surprising is that eosinophilia, 
which is typically associated with asthma, occurs in 
a subset of patients with COPD. In a recent study 
of patient data from general practice in both the 
UK and USA (around 43 000 patients), eosinophilia 
was evident in 31% and 25% of the UK and USA 
cohorts of stable COPD patients, respectively [9], 
and some studies have reported eosinophilia in 
up to 40% of patients with COPD [10]. However, 
COPD studies from the 1990s, often with small 
numbers of patients, had negative outcomes when 
looking at the effect of corticosteroid treatment on 
eosinophilic inflammation [11]. These older studies 
were used as part of the rhetoric to develop the 
concept that inflammation in COPD is corticosteroid 
insensitive, especially when contrasting with the 
effects of corticosteroid treatment for asthma. 
The first larger study to show that corticosteroids 
were effective in eosinophilic COPD was performed 
by Brightling et al. [12] almost 20 years ago. In 
their study they found that forced expiratory volume 
in 1 s and symptoms (assessed by the chronic 
respiratory disease questionnaire) were improved 
most in patients with stable COPD who had the 
highest sputum eosinophil counts. This observation 
was further strengthened by the outcomes of a 
randomised controlled trial of the treatment of 
COPD based on either British Thoracic Society 
guidelines or sputum eosinophil levels [13]. Using 
sputum eosinophil levels to guide corticosteroid 
use resulted in a 62% reduction in exacerbations.
The utility of corticosteroids 
in eosinophilic COPD  
patients
Following from these initial studies, the positive 
effect of corticosteroids in eosinophilic COPD 
patients has been consistently reproduced 
(for example, when a cut-off of 3% of sputum 
eosinophils is used) [10, 14, 15] and observed 
in post hoc analyses of recent large clinical 
trials. Post hoc analyses, while informative, are 
not ideal as disease-modifying factors such as 
severity or exacerbation frequency might not 
be fully considered in the analysis. Similarly, 
in the WISDOM trial, where corticosteroids 
were withdrawn from COPD patients, baseline 
eosinophilia predicted ICS withdrawal-related 
exacerbations of COPD [16, 17]. At this point, 
you might be wondering why the question “COPD 
treatment choices based on blood eosinophils: 
are we there yet?” was raised, if the data are so 
clear-cut. Unfortunately, there are a number of 
confounding effects, which need to be considered 
before answering this question.
The utility of measuring 
blood eosinophil 
levels in COPD
The biggest potential confounder to using blood 
eosinophil levels as a biomarker to guide treatment 
choices in either stable or exacerbating COPD 
relates to the measurement of eosinophilia, 
and the stability or reproducibility of such 
measurements. Blood eosinophil levels can 
either be expressed as an absolute count (e.g. 
150 cells·µL−1) or as a percentage of other cells 
present. Currently, individual studies define 
eosinophilia differently, or stratify patients 
according to eosinophil levels. For example, the 
groups <2%, ≥2–<3%, ≥3–<4%, <150 cells·µL−1, 
150–<300 cells·µL−1, ≥300–<400 cells·µL−1 
and ≥400 cells·µL−1 were used in the post hoc 
analysis of WISDOM [17]. Thankfully, the 2019 
treatment guidelines from the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) 
[18] have recommended blood eosinophil counts 
≥300 cells·µL−1 in stable COPD as the diagnostic 
criterion for initiating therapy with ICS/long-acting 
β-agonist (LABA). However eosinophilia is defined, 
the utility of the measurement is limited by the 
stability of the measurement. Landis et al. [19] 
explored the reproducibility of eosinophil counts 
in peripheral blood in 27 557 COPD patients with 
stable disease in general practice over 1 year 
and found an intraclass correlation coefficient 
(ICC) (a measure of how similar the individual 
measurements are to each other) of 0.64, showing 
Breathe | December 2019 | Volume 15 | No 4 321
COPD treatment choices based on blood eosinophils
that there is good reproducibility, but a subgroup 
of COPD patients have variable eosinophilia. 
Negewo et al. [20] found a better ICC of 0.8 of 
blood eosinophils over a median 28-day period 
in stable COPD, suggesting that blood eosinophil 
levels are very stable in the short term (1 month) 
in people with stable disease. Oshagbemi et al. [21] 
also carried out a study of eosinophil level 
reproducibility in general practice, including 
39 824 COPD patients and 90 772 patients 
without COPD over a 10-year period. COPD 
patients were excluded if they had an exacerbation 
within 30 days of the start of follow-up. In their 
cohort, 34.9% of COPD patients and 25.8% of 
patients without COPD had eosinophilia (defined 
as counts >0.34×109 cells·L−1). The stability 
of eosinophilia was higher in patients without 
COPD, and in patients with COPD stability was 
around 85% at 6 months, declining to 62% at 
2 years, progressively declining in subsequent 
years [21]. Other studies have found lower 
reproducibility of eosinophil counts in peripheral 
blood measurements. For example, analysis of 
a subgroup of COPD patients (334 patients) in 
the COSYCONET study [22] over routine visits at 
0, 6 and 18 months found that 26% of patients 
were non-eosinophilic at all three visits; however, 
only 5% of COPD patients were persistently 
eosinophilic. Interestingly, 28% of patients were 
eosinophilic at one study visit [22]. While the study 
visits were scheduled, patients were not excluded 
if they were exacerbating. The COSYCONET study 
analysis defined eosinophilia as ≥300 cells·µL−1, 
but when eosinophilia was defined as ≥2% in 
blood (or sputum) in a retrospective analysis of the 
ECLIPSE study [23], 37.4% of 1483 COPD patients 
had stable blood eosinophilia. This assessment 
was made based on an initial measurement of 
eosinophils at the first study visit in patients with 
stable COPD and compared to measurements at 
years 2 and 3. Sputum eosinophilia was markedly 
less reproducible, but valid measurements were 
available for approximately 10% of patients. 
Therefore, it is clear that if blood eosinophil levels 
alone were used to guide therapy, there would be 
some element of chance as to whether a given 
patient would be classified as eosinophilic or not. 
In asthma, there is good evidence to show that 
the use of β-agonists as monotherapy has pro-
inflammatory effects, for example by inducing 
sputum eosinophilia [24, 25]. Interestingly, 
this pro-eosinophilic effect of β-agonists as 
monotherapy has not been studied in COPD 
patients; however, they are safe and effective 
treatments for COPD [26].
The utility of measuring blood eosinophils 
to guide therapy is likely to vary depending 
upon the clinical status of the patient, i.e. 
whether their COPD is stable or they are 
experiencing an exacerbation. Two studies 
in 2019 have both investigated eosinophilia 
during exacerbations. MacDonald et al. [27] 
compared clinical characteristics of hospitalised 
patients with exacerbations of COPD who had 
low (<50 cells·µL−1), normal (50–150 cells·µL−1) 
or high (>150 cells·µL−1) numbers of eosinophils. 
Low eosinophil numbers were associated with 
infection, longer hospitalisation and reduced 
mortality compared to patients with high 
eosinophil counts. Sivapalan et al. [28] reported 
the results of an open-label non-inferiority trial 
of using eosinophilia (>300 cells·µL−1) to guide 
prednisolone therapy in COPD exacerbations. They 
found no significant differences in mortality or days 
out of hospital between the groups, with reduced 
corticosteroid exposure in the eosinophilia-
guided group. In a non-inferiority study, the lack 
of statistical difference between groups shows that 
the investigative treatment is as effective as the 
established treatment group. Therefore, Sivapalan 
et al. [28] demonstrate the utility of measuring 
sputum eosinophils to guide prednisolone therapy 
in COPD exacerbations. However, follow-up was 
only for 30 days, and therefore the long-term 
effects of reduced corticosteroid use during 
exacerbations remains to be determined. In the 
study by Sivapalan et al. [28], six patients died 
in the eosinophil-guided reduced corticosteroid 
group and four in the usual therapy group. While 
this difference was not statistically significant, 
mortality is a signal that needs to be closely 
followed in future studies of this nature.
Eosinophil-targeted 
therapies in COPD
So far, we have discussed the potential utility of 
using eosinophils to guide corticosteroid treatment; 
however, biological therapies targeting eosinophilia 
are emerging as useful add-on therapies for the 
treatment of severe asthma. Mepolizumab and 
benralizumab are the two leading anti-IL-5-based 
therapies, and the utility of both drugs has been 
investigated in multiple phase 3 clinical trials of 
COPD [29, 30]. For an excellent overview of the 
mepolizumab trials, see the review by Long and 
Wall [31]. The studies of both benralizumab [29] 
and mepolizumab [30] recruited eosinophilic 
COPD patients with a history of exacerbations, 
who were either receiving guideline-based 
inhaled treatment (benralizumab) or triple therapy 
(mepolizumab). The outcomes of treatment with 
the two therapies were different. Mepolizumab 
reduced exacerbation frequency in eosinophilic 
patients, but not in all patients. Benralizumab, 
however, did not affect exacerbation frequency. 
The major difference in the two studies was the 
definition of eosinophilia: in the mepolizumab 
clinical trials eosinophilia was defined as 
>220 cells·µL−1, while in the benralizumab clinical 
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trials eosinophilia was defined as ≥150 cells·µL−1 
at screening or ≥300 cells·µL−1 during the previous 
year. Exacerbation frequency in the placebo 
groups also differed (around 1.7 per year for 
mepolizumab versus 1.2 for benralizumab). Could 
these differences explain the differences in the 
study outcomes? Perhaps, and we are sure that 
these differences will be used as points of debate 
for some time to come. However, what is clear 
is that the effectiveness of these two therapies 
in COPD is markedly reduced in comparison to 
their effectiveness in asthma, and neither is likely 
to transform the management and outcomes of 
COPD patients.
COPD treatment choices 
based on blood eosinophils: 
are we there yet?
To date, the evidence suggests that measuring 
eosinophil levels to help guide therapy is useful, 
both in the context of initiating combined 
ICS/LABA, and in the potential reduction of 
corticosteroids. However, each patient is different, 
and a holistic view of their COPD needs to be taken 
before considering changes to their therapy. 
Ideally, this should include multidimensional 
assessment, as comorbidities are common 
in people with obstructive lung diseases [32]. 
The concept of identifying and treating both 
comorbidities and lung disease in COPD has given 
rise to the concept of treatable traits, which is 
described in detail in an excellent article by 
McDonald et al. [33]. Simplistically, this method 
identifies the clinical components of disease 
(pulmonary and nonpulmonary) in a patient that 
are treatable (for example high blood pressure or 
sputum eosinophilia) and treats these traits using 
a multidisciplinary approach.
The future of eosinophils 
in COPD management
The recent negative findings from the benralizumab 
trials may leave the reader with the impression that 
targeting eosinophils in COPD has limited utility. 
However, this is clearly not the case for decisions 
around introducing ICS/LABA, or reducing or 
increasing the dose of corticosteroid given in 
stable COPD. In these situations, there is good 
evidence that using eosinophil levels to guide 
corticosteroid treatment has beneficial outcomes. 
We recommend inclusion of measurement of 
eosinophils in induced sputum where possible, and 
the inclusion of blood eosinophil levels at routine 
clinical visits, as understanding how eosinophil 
levels are changing in response to treatment, or at 
the time of an exacerbation, is perhaps more useful 
than a single historical or current measurement of 
eosinophil levels. The use of a cut-off point (e.g. 
more or less than 300 cells·µL−1) is useful, but in 
our opinion eosinophil levels should be considered 
as a continuous variable. For example, an increase 
of counts from 80 to 280 cells·µL−1 would suggest 
a greater corticosteroid dose is needed, but if 
the decision was based on a cut-off point of 
300 cells·µL−1 no change in dose would occur.
As to the future of the eosinophil as simply a 
biomarker of corticosteroid responsiveness or a 
pathogenic cell in COPD, future studies are needed. 
For example, the lack of effect of benralizumab in 
reducing exacerbation frequency, despite reducing 
eosinophilic inflammation, is reasonable evidence to 
suggest that exacerbations of COPD are not driven 
by eosinophils as they are in asthma. However, this 
does not mean that, for example, reducing eosinophil 
levels in mild COPD would not be effective in reducing 
the rate of progression of COPD. It might also be 
the case that better phenotyping and selection of 
patients is needed to select patients who will benefit 
from eosinophil-targeting biological therapies.
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